СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ ГОРМОНОРЕЗИСТЕНТНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
https://doi.org/10.17650/1726-9776-2011-7-1-101-106
Аннотация
В лечении метастатического гормонорезистентного рака предстательной железы (ГРРПЖ) применение химиотерапии доцетакселом (Таксотер) как в монорежиме, так и в комбинации с другими препаратами на сегодня является стандартом. Тем не менее остается много нерешенных вопросов, связанных с его применением. Продолжается поиск препаратов, их комбинаций и новых схем терапии больных ГРРПЖ с целью улучшения результатов лечения.
Список литературы
1. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
2. N Engl J Med 2004;351:1502–12.
3. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
4. Bellmunt J. Role of chemotherapy in nonmetastatic hormone-refractory prostate cancer. Eur Urol 2009;8(Suppl):448–52.
5. Berthold D.R., Pond G.R., Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.
6. Berthold D.R., Pond G.R., Roessner M. et al. Treatment of hormonerefractory prostate cancer with docetaxel or mitoxantrone: relationship between prostatespecific antigen, pain and quality of life response and survival in the TAX 327 study. Clin Cancer Res 2008;14(9):2763–7.
7. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin Cancer Res 2007;13:6396–403.
8. Oudard S., Banu E., Medioni J. et al. What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel? J Clin Oncol 2007;25(Suppl):5149.
9. Oudard S., Banu E., Scotte F. et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18:1828–33.
10. Petrylak D.P., Ankerst D.P., Jiang C.S. et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516–21.
11. Hussain M., Goldman B., Tangen С. Use of prostate specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer: data from S9346 and S9916. J Clin Oncol 2008;26(Suppl):5015.
12. Michels J.E., Montemurro T., Murray N. et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): does sequence matter? Cancer 2006;106:1041–6.
13. Oh W.K., Manola J., Babcic V. et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235–40.
14. Berthold D.R., Pond G., de Witt R. et al., TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749–53.
15. Eymard J.C., Oudard S., Gravis G., Ferrero J.M. et al. Docetaxel reintroduction in patients with metastatic castrationresistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010;1–5.
16. Gernone A., Troccoli G., Pagliarulo V., Pagliarulo A. Retreatment with Docetaxel in metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, ASCO, San Francisco, SA USA, March 05–07, 2010; abstr 143.
17. Firek P., Pfister D.A., Thiier D. et al. Docetaxel rechallenge at PSA relapse after Docetaxel chemotherapy at hormonerefractory prostate cancer. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 93.
18. Ansari J., Choo B., Hussain S.A. et al. Docetaxel retreatment as second- and thirdline chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: An updated analysis. Genitourinary Cancers Symposium, ASCO, Orlando, FL, February 26–28, 2009; abstr 185.
19. Epplen R., Pfister D.J., Thiier D. et al. The combination of Docetaxel and Bevazizumab as a second-line therapy in patients with HRPCA and PSA relapse. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 97.
20. Heidenreich A., Pfister D.A., Thiier D. et al. Docetaxel rechallenge versus Docetaxel/Bevacizumab in castrationresistant prostate cancer following firstline Docetaxel. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 178.
21. Caffo O., Sava T., Comploj E. et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 2010;28:152–6.
22. Sartor O., Oudard S., Ozguroglu M. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 9.
23. Heidenreich A., Bolla M., Joniau S. et al. EAU guidelines on prostate cancer 2010. http://www.uroweb.org/guidelines/online-guidelines/
Рецензия
Для цитирования:
Карякин О.Б. СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ ГОРМОНОРЕЗИСТЕНТНОГО РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2011;7(1):101-106. https://doi.org/10.17650/1726-9776-2011-7-1-101-106
For citation:
Karyakin O.B. CURRENT APPROACHES TO TREATING HORMONE REFRACTORY PROSTATE CANCER. Cancer Urology. 2011;7(1):101-106. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-1-101-106
Просмотров:
735
Послать статью по эл. почте 
